Lawrence Lamb | Chief Scientific Officer
IN8bio

Dr. Lawrence Lamb leads scientific and translational strategy as scientific co-founder, Executive Vice President, and Chief Scientific Officer of IN8Bio. During his training in transplantation immunology at the South Carolina Cancer Center he was the first to describe the association between relapse-free survival and homeostatic gamma delta T cell recovery in high-risk leukemia patients. While continuing this work as an Associate Professor and later Professor of Medicine at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for chemotherapy resistant gamma delta T cell-based immunotherapy for high-grade brain tumors.  These programs led to successful IND approvals for leukemia and glioblastoma Phase I trials and a robust corporate pipeline of gamma delta T cell focused therapies.